Develops cancer therapeutics and diagnostics, focusing on enhancing treatment options and patient care.
Qualigen Therapeutics, Inc. is a pioneering biotechnology company focused on advancing innovative therapeutic solutions for cancer and infectious diseases. Established in 1996 and headquartered in Carlsbad, California, Qualigen is dedicated to developing novel treatments that address critical medical needs. The company's flagship product, FastPack, exemplifies its commitment to rapid diagnostic testing systems, offering efficient and reliable results across various healthcare settings.
Qualigen is actively engaged in groundbreaking research and development initiatives. Among its promising pipeline candidates is QN-302, aimed at revolutionizing the treatment landscape for pancreatic ductal adenocarcinoma. Additionally, the company is advancing QN-247, a DNA-coated gold nanoparticle therapeutic targeting a spectrum of cancers, highlighting its multifaceted approach to oncology innovation. Qualigen's portfolio also includes RAS-F, a small-molecule inhibitor designed to block RAS oncogene mutations and impede tumor growth, demonstrating its strategic focus on precision medicine.
Beyond oncology, Qualigen is pioneering the STARS blood cleansing system, a cutting-edge DNA/RNA-based device engineered to remove tumor-related compounds and viruses from patients' bloodstreams. With a commitment to advancing healthcare through transformative technologies, Qualigen Therapeutics, Inc. remains at the forefront of developing next-generation therapies that offer new hope to patients worldwide.